Patents by Inventor Mark Merchant

Mark Merchant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CANCER COMPRISING PD-1 AXIS BINDING ANTAGONIST AND IL6 ANTAGONIST
    Publication number: 20210332143
    Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.
    Type: Application
    Filed: March 4, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Mahrukh Huseni, Joanna E. Klementowicz, Yijin Li, Li-Fen Liu, Sanjeev Mariathasan, Mark Merchant, Luciana Molinero, Lifen Wang, Nathaniel West, Patrick Williams, Chi Yung Yuen, Edward Namserk Cha, Yulei Wang
  • COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20210169865
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 10, 2021
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
    Patent number: 10959993
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20180303815
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Application
    Filed: November 3, 2016
    Publication date: October 25, 2018
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
    Patent number: 9532987
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: January 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
    Publication number: 20160303127
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: December 17, 2015
    Publication date: October 20, 2016
    Inventors: Ellen FILVAROFF, Mark MERCHANT, Robert L. YAUCH
  • Combinations of AKT inhibitor compounds and vemurafenib, and methods of use
    Patent number: 9150548
    Abstract: The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 6, 2015
    Assignee: Genentech, Inc.
    Inventors: Klaus Hoeflich, Mark Merchant
  • COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
    Publication number: 20150125452
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Timothy R. Wilson, Hartmut Koeppen, Mark Merchant, Jeffrey Settleman
  • USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20150111869
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 23, 2015
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
    Publication number: 20150056207
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: March 5, 2014
    Publication date: February 26, 2015
    Inventors: Ellen Filvaroff, Mark Merchant, Robert L. Yauch
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE
    Publication number: 20140275106
    Abstract: The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 18, 2014
    Applicant: GENENTECH, INC.
    Inventors: Klaus Hoeflich, Mark Merchant
  • TREATMENT METHOD
    Publication number: 20110262436
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: October 14, 2009
    Publication date: October 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Brendan C. Bender, Steve Eppler, Priti Hegde, Nelson L. Jumbe, Mark Merchant, Amy C. Peterson, Arthur E. Reyes, II, Hong Xiang
  • COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
    Publication number: 20090226443
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventors: Ellen Filvaroff, Mark Merchant, Robert L. Yauch